DOCSLIB.ORG

Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Services Division and the Clinical Research Centre Ministry of Health Malaysia A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 Edited by: Lian L.M., Kamarudin A., Siti Fauziah A., Nik Nor Aklima N.O., Norazida A.R. With contributions from: Hafizh A.A., Lim J.Y., Hoo L.P., Faridah Aryani M.Y., Sheamini S., Rosliza L., Fatimah A.R., Nour Hanah O., Rosaida M.S., Muhammad Radzi A.H., Raman M., Tee H.P., Ooi B.P., Shamsiah S., Tan H.P.M., Jayaram M., Masni M., Sri Wahyu T., Muhammad Yazid J., Norafidah I., Nurkhodrulnada M.L., Letchumanan G.R.R., Mastura I., Yong S.L., Mohamed Noor R., Daphne G., Kamarudin A., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Chang K.M., Goh A.S., Sinari S., Bee P.C., Lim Y.S., Wong S.P., Omar I., Zoriah A., Fong Y.Y.A., Nusaibah A.R., Feisul Idzwan M., Ghazali A.K., Hooi L.S., Khoo E.M., Sunita B., Nurul Suhaida B.,Wan Azman W.A., Liew H.B., Kong S.H., Haarathi C., Nirmala J., Sim K.H., Azura M.A., Asmah J., Chan L.C., Choon S.E., Chang S.Y., Roshidah B., Ravindran J., Nik Mohd Nasri N.I., Ghazali I., Wan Abu Bakar Y., Wan Hamilton W.H., Ravichandran J., Zaridah S., Wan Zahanim W.Y., Kannappan P., Intan Shafina S., Tan A.L., Rohan Malek J., Selvalingam S., Lei C.M.C., Ching S.L., Zanariah H., Lim P.C., Hong Y.H.J., Tan T.B.A., Sim L.H.B, Long K.N., Sameerah S.A.R., Lai M.L.J., Rahela A.K., Azura D., Ibtisam M.N., Voon F.K., Nor Saleha I.T., Tajunisah M.E., Wan Nazuha W.R., Wong H.S., Rosnawati Y., Ong S.G., Syazzana D., Puteri Juanita Z., Mohd. Shahrir M.S., Low Y.L., Husni H., Liew L.F.E., Muhaini O., Mary S.C., Choy Y.C., Marzida M., Nur Irnawaty Z., Choo Y. M., Sapiah S., Mohd. Sufian A., Norsima Nazifah S., Nurul Faezah M.Y., Khutrun Nada Z., Md. Hanip M.R., Toh C.L., Nor Hayati A., Azizul A., Mazni M.J., Umi Adzlin S., Wong C.W.V., Noor Ratna N., Shamini R., Ang W.N., Roslina A.M., Sabrina M.S., Laila Nadrah M.Z., Valuyeetham K.A., Saraiza A.B., Suliyana Y., Aswani Yanti B., Primuharsa Putra S.H.A., Thayanithi.S., S Anusiah S., Manimegahlai S., Hana Radhiah M.D., Chuah J.L, Shamala R., Elias H., Ho B.K., Chan P.L., Saraiza A.B.,Tan K.K., Nor Saleha I.T., Rohani J., Saidatul Norbaya B., Najwa A.H. A publication of the PHARMACEUTICAL SERVICES DIVISION AND THE CLINICAL RESEARCH CENTRE MINISTRY OF HEALTH MALAYSIA MALAYSIAN STATISTICS ON MEDICINES 2008 April 2013 © Ministry of Health Malaysia Published jointly by: The National Medicines Use Survey Pharmaceutical Services Division Ministry of Health Lot 36, Jalan Universiti 46350 Petaling Jaya Malaysia Tel. : (603) 7841 3200 Fax : (603) 7968 2222 Website : http://www.pharmacy.gov.my Website : http://www.crc.gov.my AND The National Medicines Use Survey Clinical Research Centre Ministry of Health 3rd Floor, MMA House 124, Jalan Pahang 50286 Kuala Lumpur Malaysia Tel. : (603) 4043 9300 Fax : (603) 4043 9400 e-mail : [email protected] Website : http://www.crc.gov.my This report is copyrighted. Reproduction and dissemination of this report in part or in whole for research, educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Suggested citation is: Pharmaceutical Services Division and Clinical Research Centre, Ministry of Health Malaysia. Malaysian Statistics on Medicine 2008. Kuala Lumpur 2013 This report is also published electronically on website of the Pharmaceutical Services Division at: http://www.pharmacy.gov.my and the website of the Clinical Research Centre at: http://www.crc.gov.my Funding: The National Medicines Use Survey is funded by Operational Budget from Pharmaceutical Services Division, Ministry of Health. Please note that there is potential for revision of the data in this report. Please check the latest edition of Malaysian Statistics on Medicines report for any amendments at www.pharmacy.gov.my or www.crc.gov.my i MALAYSIAN STATISTICS ON MEDICINES 2008 PREFACE Ensuring access to quality and affordable medicines is an important objective of Malaysia’s National Medicines Policy. The National Medicines Use Survey (NMUS) was conducted with the intention to continuously and systematically collect data on medicines with the hope that the findings will help promote rational use as well as provide a tool for better decision making in the allocation of healthcare resources for the Malaysian population. The NMUS is into its eighth year and this report, the Malaysian Statistics on Medicines (MSOM) 2008, is its fifth publication. From the first publication of MSOM 2004, we have progressively improved and enhanced the data processing and statistical analysis methodologies. For this report, the 2007 data was reanalysed using the updated statistical methodology, taking into consideration also changes in WHO Guidelines for ATC and DDD Assignment, thus allowing comparison with the 2008 data. The drug utilisation data in this report is tabulated in such a way as to allow this comparison. The scope of NMUS and the MSOM reports are limited by data collection logistics and availability of defined daily doses (DDD) for a drug in the WHO Guidelines for ATC Classification and DDD Assignment. Nonetheless, for MSOM 2008 we are able to add two new chapters i.e. Chapter 26: Use of Drugs for Cough and Cold and Chapter 27: Use of Vaccines, using locally established DDDs based on WHO general guidelines. We are optimistic that as NMUS matures, more chapters will be added to deliberate on more classes of drugs, and future MSOM reports will continue to produce accurate and reliable statistics on Malaysian medicines consumption. The NMUS faces many challenges, not the least the varied and non-standardised form of source data and its volume. This has made data- processing and data quality assurance an almost insurmountable task. However, with perseverance, we have managed to come out with data which reflect the general quantum and pattern of medicines consumption in this country. Continued efforts will be made to improve all aspects of the survey and report, and to ensure timely publication of the data in future. We sincerely hope that this MSOM 2008 report will be useful to relevant healthcare professionals, serving as a source of reference and baseline for embarking in future research or clinical audits towards promoting rational prescribing and effective medicines use. The author(s) would like to thank the Director General Of Health Malaysia for permission to publish this report. We also would like to thank all staff, past and present, who had worked very hard in ensuring the success of the NMUS, all agencies and institutions that had helped in providing data, all expert panel members and everyone who has in one way or another contributed enthusiastically to the success of the NMUS and the writing of this report. Pharmaceutical Services Division Clinical Research Centre Ministry of Health Malaysia i MALAYSIAN STATISTICS ON MEDICINES 2008 ACKNOWLEDGEMENTS The National Medicines Use Survey would like to thank the following for their participation, assistance, support or contributions: • Director General of Health, Malaysia • Deputy Director General of Health (Research and Technical Support), Ministry of Health (MOH) • Deputy Director General of Health (Medical Services), MOH • Deputy Director General of Health (Public Health), MOH • Senior Director of Pharmaceutical Services Division, MOH • Senior Director of Oral Health Division, MOH • Director, National Pharmaceutical Control Bureau, MOH • Director, Clinical Research Centre, MOH • Heads of Clinical Services, MOH • Procurement and Privatisation Division, MOH • All medical doctors, pharmacists and support personnel who participated in the NMUS surveys • All participating public and private hospitals which provided or allowed access to their medicines procurement data • University of Malaya Medical Centre, Hospital Universiti Kebangsaan Malaysia, Hospital Universiti Sains Malaysia, Lumut Armed Forces Hospital, Terendak Armed Forces Hospital • Members of the NMUS Expert Panels who contributed to writing this report • Association of Private Hospitals Malaysia, Malaysian Organisation of Pharmaceutical Industries (MOPI) and Pharmaceutical Association of Malaysia (PhAMA) • Pharmaniaga Logistics Sdn Bhd. and Forte Tech Solutions Sdn. Bhd. • Dr. Lim Teck Onn, former Director, Clinical Research Centre, who played a pivotal role in the initiation and development of the NMUS project • All who have in one way or another supported and/or contributed to the success of the NMUS and this report Dr. Salmah binti Bahri Chairman Dr. Goh Pik Pin Co-Chairman National Medicines Use Survey, Ministry of Health Malaysia ii MALAYSIAN STATISTICS ON MEDICINES 2008 ABOUT THE NATIONAL MEDICINES USE SURVEY The National Medicines Use Survey (NMUS) is a project initiated and supported by the MOH to collect information on the supply, procurement, prescription, dispensing and use of drugs in Malaysia. The NMUS is designed to support the implementation of our National Medicines Policy (NMP). The objectives of NMP are to ensure only safe, efficacious and good quality medicines are available for use in Malaysia, as well as to promote equitable access to, and rational and cost-effective use of these medicines, ultimately leading to improved health for all Malaysians. In supporting this, the NMUS provides the functional capacity for the collection, analysis, reporting and dissemination of data on drug utilization in Malaysia. The NMUS is jointly sponsored by: • Pharmaceutical Services Division, Ministry of Health • Clinical Research Centre, National Institutes of Health, Ministry of Health Purpose of the NMUS The availability of high quality, reliable and timely information on medicines use is crucial for any discussion on improving the use of medicines in Malaysia.
Load more

Recommended publications
  • Chemistry (55)
    156 Chemistry (55) Introduction 3) To expose the students to various emerging According to NCF 2005, the new and new areas of chemistry and apprise them updated curriculum is introduced at +2 stage. with their relevance in their future studies There is a need to provide the sufficient and their applications in various spheres conceptual background of chemistry which will of chemical sciences and technology. help the students to appear for different common 4) To equip students to face various changes entrance test at the state level and the national related to health, nutrition, environment, level. This new syllabus will make them population, weather, industries and competent to meet the challenges of academic agriculture. and professional courses like medicine, 5) To develop problem solving skills in engineering, technology, etc, after the +2 stage. students. The syllabus is comparable to the international 6) To expose the students to different level. processes used in industries and their The syllabus contains areas like physical, technological applications. organic, inorganic, industrial, analytical and 7) To apprise students with interface of polymer chemistry. The upgraded syllabus has chemistry with other disciplines of science taken care of new formulations and such as physics, biology, geology, nomenclature of elements, compounds and engineering, etc. IUPAC units of physical quantities. New nomenclature, symbols and formulations, Std. XI (Theory) fundamental concepts, modern techniques are given importance. Unit 1: Some Basic Concepts of Chemistry Objectives : General Introduction: Importance and The broad objectives of teaching scope of chemistry. Historical approach to Chemistry at Higher Secondary stage are to particulate nature of matter, laws of help the learners : chemical combination, Dalton’s atomic 1) To promote understanding of basic facts theory : concept of elements, atoms and and concepts in chemistry while retaining molecules.
    [Show full text]
  • Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
    SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use.
    [Show full text]
  • Ong Edmund W 201703 Phd.Pdf (5.844Mb)
    INVESTIGATING THE EFFECTS OF PROLONGED MU OPIOID RECEPTOR ACTIVATION UPON OPIOID RECEPTOR HETEROMERIZATION by Edmund Wing Ong A thesis submitted to the Graduate Program in Pharmacology & Toxicology in the Department of Biomedical and Molecular Sciences In conformity with the requirements for the degree of Doctor of Philosophy Queen’s University Kingston, Ontario, Canada March, 2017 Copyright © Edmund Wing Ong, 2017 Abstract Opioid receptors are the sites of action for morphine and most other clinically-used opioid drugs. Abundant evidence now demonstrates that different opioid receptor types can physically associate to form heteromers. Owing to their constituent monomers’ involvement in analgesia, mu/delta opioid receptor (M/DOR) heteromers have been a particular focus of attention. Understandings of the physiological relevance of M/DOR formation remain limited in large part due to the reliance of existing M/DOR findings upon contrived heterologous systems. This thesis investigated the physiological relevance of M/DOR generation following prolonged MOR activation. To address M/DOR in endogenous tissues, suitable model systems and experimental tools were established. This included a viable dorsal root ganglion (DRG) neuron primary culture model, antisera specifically directed against M/DOR, a quantitative immunofluorescence colocalizational analysis method, and a floxed-Stop, FLAG-tagged DOR conditional knock-in mouse model. The development and implementation of such techniques make it possible to conduct experiments addressing the nature of M/DOR heteromers in systems with compelling physiological relevance. Seeking to both reinforce and extend existing findings from heterologous systems, it was first necessary to demonstrate the existence of M/DOR heteromers. Using antibodies directed against M/DOR itself as well as constituent monomers, M/DOR heteromers were identified in endogenous tissues and demonstrated to increase in abundance following prolonged mu opioid receptor (MOR) activation by morphine.
    [Show full text]
  • 1 Annex I Annex I Summary of Product Characteristics
    ANNEX I ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VENVIA 1 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains rosiglitazone maleate corresponding to 1 mg rosiglitazone. For excipients see 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets Yellow film-coated tablets marked "SB" on one side and "1" on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Rosiglitazone is indicated only in oral combination treatment of type 2 diabetes mellitus in patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea: − in combination with metformin only in obese patients. − in combination with a sulphonylurea only in patients who show intolerance to metformin or for whom metformin is contraindicated. 4.2 Posology and method of administration Treatment should only be initiated by a physician experienced in the treatment of type 2 diabetes. Experience from clinical trials with rosiglitazone is currently limited to 2 years. The long-term benefits of therapy with rosiglitazone have not been demonstrated (see section 5.1). Rosiglitazone therapy is usually initiated at 4 mg/day. Combination with Metformin This dose can be increased to 8 mg/day after 8 weeks if greater glycaemic control is required. Combination with sulphonylurea There is currently no experience with doses of rosiglitazone above 4 mg/day in combination with sulphonylureas. Rosiglitazone may be given once or twice a day. Rosiglitazone may be taken with or without food. Elderly No dose adjustment is required in the elderly. 2 Patients with renal impairment No dose adjustment is required in patients with mild and moderate renal insufficiency.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Comparison of Efficacy of Combination of 2% Ketoconazole
    Open Access Original Article Comparison of Topical Treatments in Pityriasis Versicolor Pak Armed Forces Med J 2018; 68 (6): 1725-30 COMPARISON OF EFFICACY OF COMBINATION OF 2% KETOCONAZOLE SOLUTION WASH AND TOPICAL 1% CLOTRIMAZOLE WITH TOPICAL 1% CLOTRIMAZOLE ALONE IN CASES OF PITYRIASIS VERSICOLOR Ayesha Anwar, Naeem Raza, Najia Ahmed, Hyder Ali Awan* Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Rawalpindi Pakistan, *King Abdul Aziz Naval Base, Jubail, Saudia Arabia ABSTRACT Objective: Comparison of efficacy of combination comprising 2% ketoconazole solution wash plus topical 1% clotrimazole versus topical 1% clotrimazole alone in management of patients with Pityriasis versicolor. Study Design: Randomized controlled trial. Place and Duration of Study: Dermatology department, Pak Emirates Military Hospital Rawalpindi, from Oct 2016 to Apr 2017. Material and Methods: Sixty patients of Pityriasis versicolor, both male and female were included in study. Diagnosis of Pityriasis versicolor was made clinically and confirmed microscopically by examining skin scrapings for fungal hyphae. Patients with concomitant systemic illnesses or those who had received anti-fungal in last three months were excluded from study. Random number tables were used to allocate patients to the two treatment groups. Group A received 2% ketoconazole shampoo twice per week for four weeks plus topical 1% clotrimazole twice daily application for 2 weeks. Group B received only topical therapy with 1% clotrimazole cream applied twice daily for 2 weeks. Assessment of treatment efficacy was done by clinical examination of patient and microscopy of skin scrapping for fungal hyphaedone at baseline and at end of study (4 weeks of treatment). A negative clinical examination and negative skin scrapping for fungal hyphae was considered effective therapeutic response.
    [Show full text]
  • Antibiotic Resistance in the European Union Associated with Therapeutic Use of Veterinary Medicines
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/342/99-Final Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products 14 July 1999 Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8447 E_Mail: [email protected] http://www.eudra.org/emea.html ãEMEA 1999 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS Page 1. INTRODUCTION 1 1.1 DEFINITION OF ANTIBIOTICS 1 1.1.1 Natural antibiotics 1 1.1.2 Semi-synthetic antibiotics 1 1.1.3 Synthetic antibiotics 1 1.1.4 Mechanisms of Action 1 1.2 BACKGROUND AND HISTORY 3 1.2.1 Recent developments 3 1.2.2 Authorisation of Antibiotics in the EU 4 1.3 ANTIBIOTIC RESISTANCE 6 1.3.1 Microbiological resistance 6 1.3.2 Clinical resistance 6 1.3.3 Resistance distribution in bacterial populations 6 1.4 GENETICS OF RESISTANCE 7 1.4.1 Chromosomal resistance 8 1.4.2 Transferable resistance 8 1.4.2.1 Plasmids 8 1.4.2.2 Transposons 9 1.4.2.3 Integrons and gene cassettes 9 1.4.3 Mechanisms for inter-bacterial transfer of resistance 10 1.5 METHODS OF DETERMINATION OF RESISTANCE 11 1.5.1 Agar/Broth Dilution Methods 11 1.5.2 Interpretative criteria (breakpoints) 11 1.5.3 Agar Diffusion Method 11 1.5.4 Other Tests 12 1.5.5 Molecular techniques 12 1.6 MULTIPLE-DRUG RESISTANCE
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Journal of Diabetes and Obesity
    Journal of Diabetes and Obesity Research Article Open Access The Different Association between Metformin and Sulfony- lurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index Catherine E. de Keyser1,2, Loes E. Visser1, Albert Hofman1, Bruno H. Stricker1,2*, Rikje Ruiter1# 1 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 2 The Health Care Inspectorate, The Hague, the Netherlands *Corresponding author: Bruno H. Stricker, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Netherlands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] #Submitting author: Rikje Ruiter, Department of Epidemiology, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, the Nether- lands, Tel: +31-10-7044958; Fax: +31-10-7044657; E-mail: [email protected] Abstract Received date: July 09, 2016 Aim: Several studies in large databases suggest that in comparison to glucose-low- Accepted date: : September 05, 2016 ering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer Publication date: September 12, 2016 in patients with diabetes. As many databases miss relevant confounder data, our objective was to investigate whether the determinants age, body mass index (BMI), alcohol consumption, and renal function were associated with dispensing of either Citation: Stricker, B.H., et al. The Dif- metformin or sulfonylurea derivatives as first drug therapy for type 2 diabetes mel- ferent Association between Metformin and litus while taking into account calendar time. Sulfonylurea Derivatives and the Risk of Methods: We identified 639 incident metformin users and 934 incident sulfonylurea Cancer May be Confounded by Body Mass derivatives users in the Rotterdam Study, a prospective population-based cohort Index.
    [Show full text]
  • Download Download
    Test for Acetone in Urine 189 AN IMPROVED TEST FOR ACETONE IN URINE. R. E. Lyons and J. T. Brundage, Indiana University. Lieben's test for acetone 1 depends upon the formation of iodoform when potassium iodide, iodine solution, and a few drops of sodium hydroxide solution are added to an acetone containing mixture. The iodoform is recognized by its distinctive odor and, microscopically, by the 1 star, or hexagonal crystals. The test is not specific since both ethyl alcohol and acetic aldehyde also react with these reagents to yield iodo- form. This sometimes leads to erroneous results because of alcohol formed through sugar fermentation in diabetic urine. The difficulty is obviated" by substituting ammonium hydroxide for the caustic alkali as proposed by Gunning'5 in a modification of the Lieben Test. In either test the reaction is much more sensitive if a urine dis- tillate is used. The distillation not only frees the acetone from non- volatile interfering substances, but converts some acetonacetic (di-acetic) 4 acid, if present, into acetone. Protein interferes and, if present, the separation of acetone by distillation or aeration is necessary. M. KohlthofF' states that 100 mg. each of potassium iodide and chlor- amine T, 10-20 drops of 4N ammonium hydroxide and 10 cc. of a solu- tion of one part acetone in 10,000 parts of 2 per cent ethyl alcohol when warmed to 60 °C. gave an iodoform precipitate in two hours. The object of our investigation has been to determine (a) whether this reaction could be applied as a specific test for acetone in urine, (b) what urinary constituents or preservatives interfere, (c) if the necessity of distillation, or aeration, of the urine could be dispensed with, and (d) the conditions for attaining the maximum sensitiveness of the reaction.
    [Show full text]
  • Are Metformin, Statin and Aspirin Use Still Associated with Overall Mortality Among Colorectal Cancer Patients with Diabetes If Adjusted for One Another? Zanders, M
    Tilburg University Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Zanders, M. M. J.; van Herk-Sukel, M. P. P.; Vissers, P. A. J.; Herings, R. M. C.; Haak, H. R.; van de Poll-Franse, L. V. Published in: The British Journal of Cancer DOI: 10.1038/bjc.2015.259 Publication date: 2015 Document Version Publisher's PDF, also known as Version of record Link to publication in Tilburg University Research Portal Citation for published version (APA): Zanders, M. M. J., van Herk-Sukel, M. P. P., Vissers, P. A. J., Herings, R. M. C., Haak, H. R., & van de Poll- Franse, L. V. (2015). Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? The British Journal of Cancer, 113(3), 403-410. https://doi.org/10.1038/bjc.2015.259 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]